author-photo

Birgit Bossenmaier

Hoffmann-La Roche

62

Papers

1639

Citations

Citation Trend

Filter By

Papers (45) Sort By

Journal Conference Others

Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Acquired Resistance to Antibody-Drug Conjugates

2019 Cancers
Show All
- Source
- Cite
- Save
Citations (47)
Abstract 3268: Costimulatory T-cell engagement by PRS-342, a GPC3/4-1BB bispecific molecule, leads to activation of T-cells and tumor growth inhibition in a HCC humanized mouse model

2019 Immunology
Show All
- Source
- Cite
- Save
Citations (1)
Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial

2019 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (3)
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity

2017 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (24)
Abstract 58: Local intratumoral treatment with anti-mesothelin Immunotoxins overcomes resistance to anti-CTLA-4 therapy

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

2017 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (28)
Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (22)
Impact of tumor heregulin mRNA expression on outcome of patients with advanced/metastatic squamous NSCLC treated with lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with erlotinib

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

2016 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (41)